| Cellaïon | Cellaïon是一家临床阶段的公司，致力于解决肝病患者的未满足医疗需求。 核心产品Hepastem由公司的细胞信号技术治疗平台开发。 Hepastem细胞疗法基于强大的抗炎-免疫调节作用机制，帮助肝脏的恢复、再生。迄今为止，已有100多名患者接受治疗，具备非常好的安全性，IIa期数据显示出了较好的疗效。 | Cellaïon is a clinical (phase IIb) stage company, addressing unmet medical needs in life threatening liver disease. Their lead product Hepastem is an advanced therapy, cell signaling technology platform. Hepastem has a potent anti-inflammatory-immunomodulatory mechanism of action allowing the recovery and regeneration of the liver. More than 100 patients treated so far give a huge safety profile and phase IIa data have brought the expected signals of efficacy. Pre money value is attractive, and Cellaïon is targeting conditional approval/fast track designation for its first indication, Acute on Chronic Liver Failure, in 2024. Cellaïon seeks and additional 10 mil investment to reach the next stage mid 2023, phase III and new indication, and seeks to establish partnership to develop the product in China and asian countries. |
| Atriva Therapeutics | Atriva Therapeutics是一家生物制药公司，成立于2015年，致力于宿主靶向抗病毒治疗的创新开发。公司由病毒研究领域的一流科学家和经验丰富的专家团队创立。公司力求开发全新的抗病毒疗法，以应对医疗需求远未得到满足的各种严重呼吸系统病毒感染（如流感和新冠肺炎）。 | Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19. |
| Kanova Biopharma | 鑫康合生物医药成立于2015年11月，公司基于世界前沿的科研成果，以精准创新为导向，致力于肿瘤和自身免疫性炎症疾病全新靶点或者创新性组合的药物开发，引领创新性免疫治疗抗体药物研发。目前，公司产品管线在自身免疫与肿瘤领域覆盖丰富的适应症。 | Founded in November 2015, Xinkanghe Biopharma is dedicated to the development of novel targets or innovative combinations of drugs for oncology and autoimmune inflammatory diseases, leading the development of innovative immunotherapeutic antibody drugs. Currently, the company has a rich pipeline for oncology immunology and autoimmune diseases. |
| Trevi Therapeutics | Trevi Therapeutics是一家美国制药公司，总部位于美国纽黑文。公司的核心产品Haduvio是一款纳布啡口服缓释制剂，正在开发口服纳布啡缓释剂，通过靶向中枢和外周神经系统来治疗严重的神经介导病症，如咳嗽，瘙痒等。目前特 IPF引发的慢性咳嗽的二期中期数据已公布，达到首要临床终点，日间咳嗽事件的几何平均百分比变化减少了52%（p＜0.0001)。 | Trevi Therapeutics is a NASDAQ-listed company headquartered in New Haven. The company is currently developing the investigational therapy product for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis (IPF) . These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Pruritus in prurigo nodularis (PN) is in Ph 2b/3 and interim analysis is expected 1H 2022. Chronic cough in IPF interim analysis showed primary efficacy endpoint of cough reduction was highly statistically significant (p<0.0001) and full report data is expected in Q3 2022. |
| Rational Vaccine | Rational Vaccine是一家处于研究阶段的传染病公司，致力于防治由单纯疱疹病毒1（HSV-1）和单纯疱疹病毒2（HSV-2）感染引起的所有疾病。Rational Vaccine公司的目标是开发一种适当减毒的HSV突变体作为免疫治疗剂。 | Rational Vaccine is an investigational-stage infectious disease company focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections. Rational Vaccine are aiming to develop a properly attenuated HSV mutant as an immunotherapeutic. |
| Cocrystal Pharma | Cocrystal Pharma, Inc.是一家处于临床阶段的生物技术公司，开发针对流感病毒、冠状病毒（包括SARS-CoV-2）、丙型肝炎病毒和诺如病毒复制过程的新型抗病毒治疗药物。Cocrystal采用独特的技术和获得诺贝尔奖的专业知识，创造出一流的和最佳的抗病毒药物。 | Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. |
| SynAct Pharma AB | SynAct Pharma AB是一家处于临床阶段的生物技术公司，致力于开发针对自身免疫和炎症疾病的新型口服选择性黑皮质素激动剂。核心产品AP1189，是一种每日服用一次的口服选择性黑皮素激动剂，在一项针对早期严重类风湿性关节炎的临床2a期研究中，体现出了有效性、安全性和良好的耐受性。 | SynAct Pharma AB is clinical-stage biotech focused on the development of novel oral selective melanocortin agonists targeting autoimmune and inflammatory diseases. Our lead product is AP1189 is a once-daily oral selective melanocortin agonist. AP12189 was seen to be efficacious, safe and well tolerated in a P2a study in early severe rheumatoid arthritis. |
| Henovcom | 广州市恒诺康医药科技有限公司是由多名具有丰富国际医药产业和管理经验的归国博士于2013年创办的高新技术企业，创始团队成员为曾在美国GILEAD（吉列德）、Pfize（辉瑞）以及美国FDA工作过的资深科学家，具有多年药物研究、开发和审评经验，曾参与国际上多个重磅级新药的开发。公司致力于研发具有化合物结构专利的创新药物，以满足日益增长的医疗需求。公司组建了具有国际竞争力的新药研发团队，创建了完善的新药开发技术平台和管理体系，具备一流的新药创制能力。恒诺康开发的创新药物包括新型抗病毒、抗纤维化、抗肿瘤以及中枢神经系统药物。 | Guangzhou Henovcom Bioscience Co., Ltd. was founded in 2013 by returned overseas experts with extensive experience in US biopharmaceutical industry and regulatory agency. The company has since established a highly motivated research and development team, and several highly efficient drug discovery and development platforms in areas of medicinal chemistry, API process development, analytical chemistry, pre-formulation and ADME. The founders include biopharma veterans from GILEAD, Pfizer and the US FDA each with many years of experience in biopharmaceutical research and development, as well as drug product regulatory review. They have participated in the discovery and development of several marketed blockbuster drugs. Henovcom is committed to discovering and developing innovative drugs with new chemical or molecular entities to provide new solutions for the unmet medical needs. |
| Imunopharm | 艺妙神州是一家基因细胞疗法研发商，致力于将创新的基因细胞药物技术应用于恶性肿瘤治疗。公司拥有 “一站式”基因细胞药物平台，掌握CAR-T制备的全部核心技术。该公司在血液瘤和实体瘤也布局了多个 CAR-T 细胞产品管线，其主要候选产品IM19已进入临床II期，预计2022年NDA。 | Imunopharm is a gene cell therapy developer devoted to developing innovative gene and cell therapies for curing malignant tumors. Imunopharm has “One-stop” gene and cell platform, covering all core technologies for CAR-T cell production. The company also has several CAR-T cell product pipelines in haematology and solid tumours, with its lead product IM19 CAR-T cells which target CD19 is currently in clinical phase II and NDA is expected in Q4 2022 |
| Sinocelltech | 北京神州细胞生物技术集团股份公司专注于单克隆抗体、重组蛋白、疫苗等生物药产品的研发和产业化。公司管理团队拥有丰富的生物药研发和生产经验，目前共有23余款在研产品，专注于创新生物药和高端生物药，具有明显的成本竞争优势。 | Sinocelltech has 20+ years biotechnology accumulation history, 23+ products in pipeline, focus on biosimilar and bio-better products, significant cost-competitive advantage. |
| PersonGen BioTherapeutics | PersonGen BioTherapeutics是一家全球化的临床阶段的生物制药公司，专注于开发领先的细胞疗法，拥有最先进的全自动化封闭式细胞疗法制造系统，以及最先进的临床级DNA质粒和慢病毒载体生产。PersonGen公司产品管线包括治疗血液恶性肿瘤和实体瘤的多种自体和异体候选产品，包括最佳潜力的PA3-17（CD7 CAR-T）、TAA06-CAR-T（B7-H3 CAR-T）和TAA05-CAR-T（FLT3 CAR-T）等等。PA3-17临床试验已获中国药监局批准，用于治疗复发/难治性急性T淋巴细胞白血病和淋巴瘤的一期临床试验，并已被美国药监局授予 “孤儿药 “称号。PA3-17的初步临床试验显示了良好的疗效和安全性。PA3-17的NDA预计将在2024年完成，这是PersonGen公司的战略计划是寻找一个优质的合作伙伴来合作进行全球商业化。TAA06 CAR-T是PersonGen公司的另一项主要资产，已被美国FDA授予 “孤儿 “药物（ODD）和罕见儿科疾病（RPD）的称号。TAA06 CAR-T也有望在今年7月获得NMPA的IND批准，用于治疗神经母细胞瘤，以及其他实体瘤（胰腺癌和胶质母细胞瘤）。PersonGen公司还在寻求优质合作伙伴的机会，共同开发针对实体瘤的B7-H3-CAR-T。 | PersonGen BioTherapeutics is a global clinical-stage biopharmaceutical company focusing on developing leading-edge cellular therapeutics, and is equipped with the state of art fully-automated, closed manufacturing system for cellular therapeutics, as well as with most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. Leveraging its pioneering R&D platforms, PersonGen is developing a comprehensive but differentiated clinical-stage pipeline of multiple autologous and allogeneic product candidates for hematological malignancies and solid tumors, including first-in-class and best-in class potential PA3-17 (CD7 CAR-T), TAA06-CAR-T (B7-H3 CAR-T), and TAA05-CAR-T (FLT3 CAR-T) etc. PA3-17 IND has been approved by NMPA (Chinese FDA) for phase 1 clinical trial for the treatment of relapsed/refractory acute T lymphoblastic leukemia and lymphoma, and also has been granted designation of Orphan Drug (ODD) by FDA. Initial clinical trial of PA3-17 exhibited promising efficacy and safety results. NDA of PA3-17 is expected in 2024 and is PersonGen’s immediate priority of strategic planning for a quality partner to collaborate in the global commercialization. TAA06 CAR-T, PersonGen’s another leading asset, has been granted designation of Orphan Drug (ODD) and Rare Pediatric Disease (RPD) by US FDA. TAA06 CAR-T is also expecting for IND approval by NMPA in coming July for treating Neuroblastoma, as well as other solid tumors thereafter (pancreatic cancer and glioblastoma). PersonGen is also seeking quality partners’ opportunities to co-develop the B7-H3-CAR-T against solid tumors. |
| Immunwork | 免疫功坊于 2014 年 10 月成立，利用独特的技术平台来研究、发展、以及商业化一系列新药，用以治疗数种癌症、自体免疫疾病、传染性疾病、骨质疏松症、中枢神经系统疾病、病理性血栓、器官移植排斥反应、及其他数种重大疾病。 | Founded in 2014, Immunwork initiative comes from the concept of “T-E pharmaceuticals”, in which the drug molecules should contain both targeting (T) and effector (E) moieties. Based on this concept, Immunwork, develops proprietary “multi-arm linker” platforms to conjugate various moieties together to create new drugs, including ADCs and peptides to treat cancer, diabetes, NASH, obesity, pathological blood clots, osteoporosis, and other selected severe clinical conditions. We are looking forward to bringing our drug candidates to clinical applications and help those who are in need. Furthermore, the multi-arm linker platform should be applicable for designing additional novel drug candidates. |
Skin/Respiratory/Infectious/Cell Therapy – June 24 | Summer showcase 2022
BioToChina.org 